Key result
Low-dose aspirin benefits high-risk patients but lacks primary prevention value in older adults due to bleeding.
Why the study?
Evidence has accrued on low-dose aspirin's therapeutic potential extending beyond cardiovascular applications, changing the future of aspirin use across different fields of medicine.
Population
Non-coronary artery disease populations across diverse medical fields
Comparison
Low-dose aspirin use across various non-cardiovascular indications
Design
Structured narrative review
Authors
Loading...
May support LDA consideration in select non-CVD settings with bleeding caution; leaves open dedicated RCTs for confirmation.
Low-dose aspirin has multifaceted preventive applications beyond coronary artery disease, particularly in preeclampsia, specific colorectal cancers, and antiphospholipid syndrome, though its use must be balanced against bleeding risks.
Soliman et al. (2026) conducted a review in Conditions beyond coronary artery disease (e.g., preeclampsia, cancer, rheumatic diseases). Low-dose aspirin was evaluated. Low-dose aspirin provides significant benefits in specific high-risk populations, such as reducing preeclampsia risk and lowering recurrence of PIK3CA-mutated stage II-III colon cancer by nearly 50%, but routine primary prevention in older adults is not recommended due to bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: